Response to Cersosimo
- David S. Schade, MD1 and
- Virginia Valentine, CNS, BC-ADM, CDE2
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico
- 2Clinical Associate Faculty-University of New Mexico College of Nursing, Diabetes Network, Albuquerque, New Mexico
We thank Dr. Cersosimo for his letter addressing our editorial and are pleased to address his concerns (1,2). In our article “To Pump or Not to Pump?” (2), we pointed out that both emotions and scientific evidence have contributed to the debate on the role of continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI). It is worth remembering that the only real benefit of CSII relates to the kinetics of delivery of subcutaneous insulin. We emphasized that all previous studies in which NPH insulin was used as the background insulin in MDI were of limited value because insulin glargine now provides a more physiological insulin profile (3). In addition, very …
